Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $132.00 at Robert W. Baird

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective boosted by Robert W. Baird from $67.00 to $132.00 in a report issued on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other brokerages have also recently commented on DNTH. Truist Financial upped their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Wedbush upped their target price on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Oppenheimer increased their target price on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a report on Monday. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $115.33.

Dianthus Therapeutics Stock Up 9.7%

Shares of Dianthus Therapeutics stock opened at $86.92 on Tuesday. The business has a fifty day simple moving average of $50.09 and a 200 day simple moving average of $41.61. The stock has a market cap of $3.76 billion, a PE ratio of -21.20 and a beta of 1.56. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $86.97.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 41.34%. The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of DNTH. Virtus Investment Advisers LLC lifted its stake in Dianthus Therapeutics by 7.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after acquiring an additional 416 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics News Summary

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the phase 3 CAPTIVATE CIDP trial after an interim responder analysis — company met GO criteria with 20 confirmed responders and will keep the Part A dose, accelerating development and creating a near‑term catalyst (top‑line CIDP data expected year‑end 2026). Globe Newswire — Early GO Decision
• Positive Sentiment: Encouraging clinical update drove sharp intraday gains — multiple outlets report shares jumped after the interim data and management commentary indicating the program is advancing (investor enthusiasm for a late‑stage autoimmune asset). Investing.com — Stock Surges on CIDP Trial Success
• Positive Sentiment: Multiple analyst upgrades and big price‑target increases (Raymond James to strong‑buy/$123, Robert W. Baird to $132, HC Wainwright to $130, Truist to $110, Guggenheim reiteration) are reinforcing bullish sentiment and providing supporting coverage. Yahoo Finance — Guggenheim Reiterates Buy
• Neutral Sentiment: Analyses and writeups are re‑examining DNTH valuation after large share gains (12–13x over two years); these pieces help frame risk/reward but don’t change near‑term fundamentals. Investors.com — What’s Going On?
• Neutral Sentiment: Company disclosed an AI integration-related cyber/privacy/reputational risk in filings — worth monitoring operationally but not an immediate stock driver versus clinical and financing news. TipRanks — AI Integration Risk
• Negative Sentiment: Announced proposed $400M underwritten public offering (plus 30‑day option for up to $60M) — dilutive capital raise that triggered a stock pullback as investors weigh share issuance against cash runway and program funding. Globe Newswire — $400M Offering
• Negative Sentiment: Q4 earnings missed consensus (loss of $1.43 vs. est. ~$0.97), highlighting ongoing operating losses and the company’s need for external funding — a reminder that clinical progress, not current revenue, is the primary value driver. Zacks — Q4 Loss, Miss

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.